BioCryst Reports Q1 2026 Earnings with Revenue Growth and Operational Updates
BioCryst Pharmaceuticals (BCRX) reported Q1 2026 earnings with net revenue of $148.3 million, a 21% increase year-over-year excluding the European divestiture impact. The company also noted a 25% year-over-year increase in non-GAAP operating profit to $54 million and a $261 million liquidity position.
Tickers: $BCRX
Topics: acquisition non-GAAP operating profit pharmaceuticals revenue